The safety of stopping nucleos(t)ide analogue treatment in patients with HBeAg-negative chronic hepatitis B.
Grace Lai-Hung WongHenry L-Y ChanBecky W-Y YuenYee-Kit TseHester W-S LukTerry Cheuk Fung YipVicki W-K HuiLilian Y LiangHye-Won LeeGrace C-Y LuiVincent Wai-Sun WongPublished in: Liver international : official journal of the International Association for the Study of the Liver (2019)
Hepatitis flare and retreatment were common in HBeAg-negative CHB patients who stopped NA treatment; whereas HBsAg seroclearance rarely occurred. Stopping NA to achieve functional cure should not be recommended at this moment.
Keyphrases